Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565930 | 0.81 | MAPT (0.42) | METAP1METAP2 | |
| SCHEMBL13582 | 0.78 | METAP1 (0.49) | METAP1METAP2ALOX5EPHX1HPGD | |
| SCHEMBL931400 | 0.78 | METAP1 (0.49) | METAP1METAP2ALOX5EPHX1HPGD | |
| SCHEMBL6937033 | 0.76 | METAP1 (0.43) | METAP1METAP2ALOX5EPHX1HPGD | |
| SCHEMBL1814190 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 | |
| SCHEMBL3958667 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 | |
| SCHEMBL3966987 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 | |
| SCHEMBL3958285 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 | |
| SCHEMBL3958289 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 | |
| SCHEMBL3961044 | 0.76 | METAP1 (0.44) | METAP1METAP2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | METAP1 139/4885METAP2 506/4885ALOX5 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.